Summit Therapeutics

Summit Therapeutics

Yahoo Finance • 2 days ago

Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Summit Therapeutics Inc. (NASDAQ:SMMT) withdrew a $500 million proposed underwritten public offering it ha... Full story

Yahoo Finance • 12 days ago

Summit rebounds after nearly $50M insider purchase

[$10 Banknote Stacking, Green Up Arrow Rise] spawns * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) bounced back, recovering recent losses on Friday after the cancer drug developer’s co-CEO Robert Duggan di... Full story

Yahoo Finance • 14 days ago

Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.87%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.98%.  June E-mini S&P futures (ESM26) fell -1.62%, and... Full story

Yahoo Finance • 14 days ago

Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%.  June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Na... Full story

Yahoo Finance • 14 days ago

Stocks Fall on Weakness in Tech and Trucking Companies

The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.28%.  June E-mini S&P futures (ESM26) are down -0.25%, and June E-mini Na... Full story

Yahoo Finance • 15 days ago

Summit Therapeutics Announces Proposed Public Offering of Common Stock

MIAMI, June 09, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) ("Summit," "we," or the "Company") today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of... Full story

Yahoo Finance • 17 days ago

Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Manmeet Soni, COO, CFO & Director of the company, who spent a stonking US$722k on stock at an average price of... Full story

Yahoo Finance • 19 days ago

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 31, Summit Therapeutics Inc. (NASDAQ:SMMT) presented new clinical data from the international Phase II AK112-206... Full story

Yahoo Finance • 22 days ago

Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best short squeeze stocks to invest in. On May 22, Cantor Fitzgerald restated its Overweight rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm addressed concerns about the HA... Full story

Yahoo Finance • 24 days ago

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an a... Full story

Yahoo Finance • last month

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.... Full story

Yahoo Finance • last month

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • last month

Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.73%.  June E-mini S&P futures (ESM26) are up +0.47%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • last month

Stocks Supported by US-Iran Peace Deal Optimism

The S&P 500 Index ($SPX) (SPY) today is up +0.54%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.70%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.53%.  June E-mini S&P futures (ESM26) are up +0.50%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • last month

Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?

Earlier in May 2026, Revolution Medicines reported that its RAS(ON) inhibitor daraxonrasib delivered what it called unprecedented overall survival benefit in the pivotal Phase 3 RASolute 302 trial for metastatic pancreatic cancer, while al... Full story

Yahoo Finance • 2 months ago

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binar... Full story

Yahoo Finance • 2 months ago

This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market

Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and a $45 price target.... Full story

Yahoo Finance • 2 months ago

Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch

Summit Therapeutics stock crashed Friday after the company said its lung cancer treatment didn't pass muster at an interim analysis. Continue Reading... Full story

Yahoo Finance • 2 months ago

Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026

(RTTNews) - Summit Therapeutics Inc. (SMMT) reported financial results for the first quarter ended March 31, 2026, reflecting a wider net loss and provided clinical and operational progress for its lead candidate, Ivonescimab. Company Pro... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story